T
Teresa Palomero
Researcher at Columbia University
Publications - 75
Citations - 7997
Teresa Palomero is an academic researcher from Columbia University. The author has contributed to research in topics: T cell & Signal transduction. The author has an hindex of 35, co-authored 70 publications receiving 7296 citations. Previous affiliations of Teresa Palomero include Brigham and Women's Hospital & Columbia University Medical Center.
Papers
More filters
Journal ArticleDOI
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero,Maria Luisa Sulis,Maria Cortina,Pedro J. Real,Kelly Barnes,Maria Ciofani,Esther Caparrós,Jean Buteau,Kristy A. Brown,Sherrie L. Perkins,Govind Bhagat,Archana M. Agarwal,Giuseppe Basso,Mireia Castillo,Satoru Nagase,Carlos Cordon-Cardo,Ramon Parsons,Juan Carlos Zúñiga-Pflücker,Maria Dominguez,Adolfo A. Ferrando +19 more
TL;DR: Findings identify transcriptional control of PTEN and regulation of the PI3K-AKT pathway as key elements of the leukemogenic program activated by NOTCH1 and provide the basis for the design of new therapeutic strategies for T-ALL.
Journal ArticleDOI
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth
Teresa Palomero,Wei Keat Lim,Duncan T. Odom,Maria Luisa Sulis,Pedro J. Real,Adam A. Margolin,Kelly Barnes,Jennifer O'Neil,Donna Neuberg,Andrew P. Weng,Jon C. Aster,François Sigaux,Jean Soulier,A. Thomas Look,Richard A. Young,Andrea Califano,Adolfo A. Ferrando +16 more
TL;DR: In this paper, the authors used an integrative systems biology approach to identify c-myc as an essential mediator of NOTCH1 signaling and integrate NOTCH 1 activation with oncogenic signaling pathways upstream of c-MYC.
Journal ArticleDOI
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia
Benjamin J. Thompson,Silvia Buonamici,Maria Luisa Sulis,Teresa Palomero,Tomas Vilimas,Giuseppe Basso,Adolfo A. Ferrando,Iannis Aifantis +7 more
TL;DR: The data suggest that FBW7 is a novel tumor suppressor in T cell leukemia, and implicate the loss ofFBW7 function as a potential mechanism of drug resistance in T-ALL.
Journal ArticleDOI
γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia
Pedro J. Real,Valeria Tosello,Teresa Palomero,Teresa Palomero,Mireia Castillo,Eva Hernando,Elisa de Stanchina,Maria Luisa Sulis,Maria Luisa Sulis,Kelly Barnes,Catherine M. Sawai,Irene Homminga,Jules P.P. Meijerink,Iannis Aifantis,Giuseppe Basso,Carlos Cordon-Cardo,Weiyun Z. Ai,Adolfo A. Ferrando,Adolfo A. Ferrando +18 more
TL;DR: It is shown that combination therapy with GSIs plus glucocorticoids can improve the antileukemic effects of GSIs and reduce their gut toxicity in vivo and support a role for glucocORTicoid-resistant T-ALL.
PatentDOI
Recurrent mutations in epigenetic regulators, rhoa and fyn kinase in peripheral t-cell lymphomas
TL;DR: In this paper, the authors identified highly recurrent epigenetic factor mutations in TET2, DN-MT3A and IDH2 as well as a new highly prevalent RHOA p.Gly17Val (NM_001664) mutation present in 22/35 (67%) of angioimmunoblastic T-cell lymphomas (AITL) and in 8/44 (18%) not otherwise specified PTCL (PTCL NOS) samples.